Download Product Information

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Adherence (medicine) wikipedia , lookup

Multiple sclerosis research wikipedia , lookup

Management of multiple sclerosis wikipedia , lookup

Transcript
Attachment 1: Product information for AusPAR Remicade Janssen-Cilag Pty Ltd PM-201100196-3-1 Final 17 December 2012. This Product Information was approved at the time this
AusPAR was published.
Paediatric Malignancy
Post-marketing cases of malignancies, some fatal, have been reported among children,
adolescents and young adults (up to 22 years of age) who received TNF-blocking agents
(initiation of therapy ≤ 18 years of age), including REMICADE, to treat Juvenile Idiopathic
Arthritis (JIA), Crohn’s disease or other conditions. Approximately half the reports were
lymphomas (Hodgkin’s and non-Hodgkin’s lymphoma). The other cases represented a
variety of different malignancies and included malignancies that are not usually observed in
children and adolescents.
Most of the patients were receiving concomitant
immunosuppressants, such as methotrexate, azathioprine or 6-mercaptopurine. The role of
TNF blockers in the development of malignancies in children and adolescents remains
unclear.
Hepatosplenic T-cell lymphomas
Rare postmarketing cases of hepatosplenic T-cell lymphoma have been reported in patients
treated with TNF-blocking agents including REMICADE. This rare type of T-cell lymphoma
has a very aggressive disease course and is usually fatal. All REMICADE cases have
occurred in patients with Crohn's disease or ulcerative colitis and the majority were reported
in adolescent or young adult males. All of these patients had received treatment with
azathioprine or 6-mercaptopurine concomitantly with or immediately prior to REMICADE.
*It is uncertain whether the occurrence of the HSTCL is related to REMICADE or
REMICADE in combination with these other immunosuppressants. When treating patients
with inflammatory bowel disease, particularly in adolescents and young adults, consideration
of whether to use REMICADE alone or in combination with other immunosuppressants
should take into account a possibility that there is a higher risk of HSTCL with combination
therapy versus an observed increased risk of immunogenicity and hypersensitivity reactions
with REMICADE monotherapy from the clinical trial data.
Leukaemia
Cases of acute and chronic leukaemia have been reported with post-marketing TNF-blocker
use in rheumatoid arthritis and other indications. Even in the absence of TNF blocker
therapy, patients with rheumatoid arthritis may be at a higher risk (approximately 2-fold) than
the general population for the development of leukaemia.
*Colon Carcinoma/Dysplasia
All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma
(for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis),
or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia
at regular intervals before therapy and throughout their disease course. This evaluation
should include colonoscopy and biopsies per local recommendations. With current data it is
not known if REMICADE treatment influences the risk for developing dysplasia or colon
cancer (see ADVERSE EFFECTS section).
Since the possibility of increased risk of cancer development in patients with newly
diagnosed dysplasia treated with REMICADE is not established, the risk and benefits to the
individual patients must be carefully reviewed and consideration should be given to
discontinuation of therapy.
Auto-immune processes
The relative deficiency of TNF caused by anti-TNF therapy may result in the initiation of an
autoimmune process in a subgroup of genetically susceptible patients. If drug-induced lupus is
suspected, patients being treated with REMICADE should have regular measurements of
Antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies. If a patient
develops symptoms suggestive of a lupus-like syndrome following treatment with REMICADE
REMICADE (120507) API
Page 21